ERASCA INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | ERAS |
| ISIN: |
ERASCA INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
ERASCA INC. - More news...
ERASCA INC. - More news...
- 08/24/2022 - 12:00 Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
- 08/23/2022 - 12:00 Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
- 08/11/2022 - 20:05 Erasca Reports Second Quarter 2022 Financial Results and Business Updates
- 07/18/2022 - 12:00 Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
- 06/03/2022 - 13:00 Erasca to Present at the 2022 Jefferies Healthcare Conference
- 05/25/2022 - 12:00 Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments
- 05/12/2022 - 20:01 Erasca Reports First Quarter 2022 Financial Results and Business Updates
- 04/12/2022 - 20:01 Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting
- 03/24/2022 - 20:05 Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
- 01/18/2022 - 13:00 Erasca Strengthens Leadership Team with Two Key Executive Appointments
- 12/17/2021 - 13:00 Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial
- 12/14/2021 - 13:00 Erasca Added to the Nasdaq Biotechnology Index
- 11/16/2021 - 13:00 Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
- 11/10/2021 - 21:05 Erasca Reports Third Quarter 2021 Financial Results and Business Updates
- 10/25/2021 - 20:01 Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
- 09/27/2021 - 12:01 Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021
- 09/22/2021 - 12:00 Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
- 09/09/2021 - 12:00 Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
- 09/02/2021 - 12:00 Erasca to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Conference
- 08/26/2021 - 20:01 Erasca Reports Second Quarter 2021 Financial Results and Business Updates
- 07/20/2021 - 20:01 Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
